{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:10:38Z","timestamp":1788667838719,"version":"build-2803163510"},"reference-count":22,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mirikizumab, a selective interleukin-23p19 inhibitor, has demonstrated efficacy in randomized controlled trials for moderate-to-severe ulcerative colitis (UC). However, long-term real-world data remain limited, particularly in treatment-experienced populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the 52-week real-world effectiveness and safety of mirikizumab in a treatment-experienced UC cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Two-center international retrospective observational cohort study of adults with active UC initiating mirikizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study expands a previously published 12-week real-world cohort from the same centers, adding patients and extending follow-up to 52 weeks. The primary outcome was clinical remission (SCCAI \u22642) at week 52 using non-responder imputation. Secondary outcomes included clinical response, corticosteroid-free remission, and drug persistence at weeks 12, 26, and 52, as well as safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort included 120 patients with prior anti-TNF, vedolizumab, and JAK inhibitor exposure in 75.8%, 75.0%, and 42.5%, respectively. Clinical response rates were 67.5%, 52.3%, and 41.3% at weeks 12, 26, and 52, with corresponding remission rates of 14.2%, 19.8%, and 28.3% (modified NRI: 35.6%). Corticosteroid-free remission at 52 weeks was 26.1%. Drug persistence at 52 weeks was 64.6% (95% CI 54.9\u201372.7%), without significant differences by prior biologic exposure class. Among 60 patients (50.0%) receiving extended induction, week-26 remission was lower than in standard induction recipients (10.7% vs. 29.1%; p=0.018). Adverse events occurred in 13 patients (10.8%), leading to discontinuation in 5 (4.2%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this large treatment-experienced real-world UC cohort, mirikizumab achieved 52-week clinical remission in 28.3% and drug persistence of 64.6%, with no new safety signals identified, supporting its role across lines of therapy in UC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562848261487334","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:54:54Z","timestamp":1788562494000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term real-world effectiveness and safety of mirikizumab in ulcerative colitis: 52-Week results from an expanded international two-center retrospective cohort study"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1235-1927","authenticated-orcid":false,"given":"Asaf","family":"Levartovsky","sequence":"first","affiliation":[{"name":"Sheba Medical Center"},{"name":"Tel Aviv University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Luk\u00e1\u0161","sequence":"additional","affiliation":[{"name":"ISCARE a.s. and 1st Medical Faculty Charles University"},{"name":"Charles University and Kralovske Vinohrady University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaya Mushka","family":"Abitbol","sequence":"additional","affiliation":[{"name":"Sheba Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate\u0159ina","family":"Vlkov\u00e1","sequence":"additional","affiliation":[{"name":"ISCARE a.s. and 1st Medical Faculty Charles University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3984-4580","authenticated-orcid":false,"given":"Shomron","family":"Ben-Horin","sequence":"additional","affiliation":[{"name":"Sheba Medical Center"},{"name":"Tel Aviv University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Luk\u00e1\u0161","sequence":"additional","affiliation":[{"name":"ISCARE a.s. and 1st Medical Faculty Charles University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7156-0588","authenticated-orcid":false,"given":"Uri","family":"Kopylov","sequence":"additional","affiliation":[{"name":"Sheba Medical Center"},{"name":"Tel Aviv University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.06.016"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000000536"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00768-1"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01909-1"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2207940"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otaf002"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae253"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae004"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2025.00176"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.70140"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2025-002232"},{"issue":"10","key":"e_1_3_7_14_2","doi-asserted-by":"crossref","first-page":"e0334897","DOI":"10.1371\/journal.pone.0334897","article-title":"Sequencing Therapy for Optimal Response in Mirikizumab (STORM)-study: A tertiary referral center study on patients with therapy-refractory ulcerative colitis","volume":"20","author":"Kubesch A","year":"2025","unstructured":"Kubesch A, Lande R, Leutg\u00f6b A, et al. Sequencing Therapy for Optimal Response in Mirikizumab (STORM)-study: A tertiary referral center study on patients with therapy-refractory ulcerative colitis. PLoS One 2025; 20(10 October): e0334897. https:\/\/doi.org\/10.1371\/journal.pone.0334897","journal-title":"PLoS One"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjag062"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562848251392074"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_3_7_18_2","article-title":"Mirikizumab is Equally Effective in Ustekinumab-Exposed and Ustekinumab-Na\u00efve Patients with UC: A Multicentre Real-World Cohort","volume":"360","author":"Sharip MT","year":"2026","unstructured":"Sharip MT, Durai D, Vayreda E, et al. Mirikizumab is Equally Effective in Ustekinumab-Exposed and Ustekinumab-Na\u00efve Patients with UC: A Multicentre Real-World Cohort. Crohns Colitis 2026; 360. https:\/\/doi.org\/10.1093\/crocol\/otag065","journal-title":"Crohns Colitis"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1159\/000551500"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaf018"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.70214"},{"issue":"2","key":"e_1_3_7_22_2","first-page":"148","article-title":"Multicentre retrospective real-world evidence study evaluating the effectiveness and safety of mirikizumab in patients with moderately to severely active ulcerative colitis","volume":"21","author":"Lamparski \u0141","year":"2026","unstructured":"Lamparski \u0141, Kar\u0142owicz K, Tulewicz-Marti E, et al. Multicentre retrospective real-world evidence study evaluating the effectiveness and safety of mirikizumab in patients with moderately to severely active ulcerative colitis. Prz Gastroenterol 2026; 21(2): 148\u2013159. https:\/\/doi.org\/10.5114\/pg.2026.161906","journal-title":"Prz Gastroenterol"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003407"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848261487334","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562848261487334","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848261487334","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T03:31:22Z","timestamp":1788665482000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562848261487334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":22,"alternative-id":["10.1177\/17562848261487334"],"URL":"https:\/\/doi.org\/10.1177\/17562848261487334","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"value":"1756-2848","type":"print"},{"value":"1756-2848","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"17562848261487334"}}